BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 28643021)

  • 1. The effect of 14-3-3ζ expression on tamoxifen resistance and breast cancer recurrence: a Danish population-based study.
    Thistle JE; Hellberg Y; Mortensen K; Hamilton-Dutoit S; Kjærsgaard A; Cronin-Fenton D; Sørensen HT; Lash TL
    Breast Cancer Res Treat; 2017 Oct; 165(3):633-643. PubMed ID: 28643021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study.
    Hjorth CF; Nielsen AS; Sørensen HT; Lash TL; Damkier P; Hamilton-Dutoit S; Cronin-Fenton D
    Acta Oncol; 2019 Feb; 58(2):168-174. PubMed ID: 30458661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.
    Ahern TP; Cronin-Fenton DP; Lash TL; Sørensen HT; Ording AG; Hamilton-Dutoit SJ; Hellberg Y
    Acta Oncol; 2016 Jun; 55(6):734-41. PubMed ID: 27056567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-inducible factor-1α expression and breast cancer recurrence in a Danish population-based case control study.
    Collin LJ; Maliniak ML; Cronin-Fenton DP; Ahern TP; Christensen KB; Ulrichsen SP; Damkier P; Hamilton-Dutoit S; Yacoub R; Christiansen PM; Sørensen HT; Lash TL
    Breast Cancer Res; 2021 Nov; 23(1):103. PubMed ID: 34736510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.
    Lash TL; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Garne JP; Sørensen HT; Hellberg Y; Christensen M; Pedersen L; Hamilton-Dutoit S
    J Natl Cancer Inst; 2011 Mar; 103(6):489-500. PubMed ID: 21325141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein D expression does not predict breast cancer recurrence among tamoxifen-treated patients.
    Klebaner D; Hamilton-Dutoit S; Ahern T; Crawford A; Jakobsen T; Cronin-Fenton DP; Damkier P; Janssen E; Kjaersgaard A; Ording AG; Søiland H; Sørensen HT; Lash TL; Hellberg Y
    PLoS One; 2017; 12(3):e0171453. PubMed ID: 28301514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of survivin does not appear to influence breast cancer recurrence risk.
    Collin LJ; Cronin-Fenton DP; Ahern TP; Christensen KB; Damkier P; Hamilton-Dutoit S; Kjaersgaard A; Lauridsen KL; Yacoub R; Christiansen P; Sørensen HT; Lash TL
    Acta Oncol; 2019 Feb; 58(2):154-161. PubMed ID: 30351173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
    Bergamaschi A; Christensen BL; Katzenellenbogen BS
    Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors.
    Ahern TP; Christensen M; Cronin-Fenton DP; Lunetta KL; Søiland H; Gjerde J; Garne JP; Rosenberg CL; Silliman RA; Sørensen HT; Lash TL; Hamilton-Dutoit S
    Cancer Epidemiol Biomarkers Prev; 2011 Sep; 20(9):1937-43. PubMed ID: 21750172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in Denmark.
    Collin LJ; Cronin-Fenton DP; Ahern TP; Christiansen PM; Damkier P; Ejlertsen B; Hamilton-Dutoit S; Kjærsgaard A; Silliman RA; Sørensen HT; Lash TL
    BMJ Open; 2018 Aug; 8(7):e021805. PubMed ID: 30068618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
    Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
    Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study.
    Cronin-Fenton DP; Hellberg Y; Lauridsen KL; Ahern TP; Garne JP; Rosenberg C; Silliman RA; Sørensen HT; Lash TL; Hamilton-Dutoit S
    Acta Oncol; 2012 Feb; 51(2):254-61. PubMed ID: 22129357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.
    Lundgren C; Bendahl PO; Ekholm M; Fernö M; Forsare C; Krüger U; Nordenskjöld B; Stål O; Rydén L
    Breast Cancer Res; 2020 Dec; 22(1):140. PubMed ID: 33357231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Over-expression of miR-451a can enhance the sensitivity of breast cancer cells to tamoxifen by regulating 14-3-3ζ, estrogen receptor α, and autophagy.
    Liu ZR; Song Y; Wan LH; Zhang YY; Zhou LM
    Life Sci; 2016 Mar; 149():104-13. PubMed ID: 26896688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and clinicopathological significance of DNA methyltransferase 1, 3A and 3B in tamoxifen-treated breast cancer patients.
    Jahangiri R; Jamialahmadi K; Gharib M; Emami Razavi A; Mosaffa F
    Gene; 2019 Feb; 685():24-31. PubMed ID: 30359738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer.
    Liu B; Wang T; Wang H; Zhang L; Xu F; Fang R; Li L; Cai X; Wu Y; Zhang W; Ye L
    J Hematol Oncol; 2018 Feb; 11(1):26. PubMed ID: 29471853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer.
    Madhavan S; Gusev Y; Singh S; Riggins RB
    J Exp Clin Cancer Res; 2015 May; 34(1):45. PubMed ID: 25971350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
    Habel LA; Shak S; Jacobs MK; Capra A; Alexander C; Pho M; Baker J; Walker M; Watson D; Hackett J; Blick NT; Greenberg D; Fehrenbacher L; Langholz B; Quesenberry CP
    Breast Cancer Res; 2006; 8(3):R25. PubMed ID: 16737553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.